Vulnerable Plaques, Vulnerable Patients, and Intravascular Imaging ∗

Journal of the American College of Cardiology

Volumn 72, Issue 17, 2018, Pages 2022-2026

  Stone, Gregg W ^a,b   Mintz, Gary S ^b   Virmani, Renu ^c  

^a Department of Medicine   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c CVPATH INSTITUTE   (United States)

Author keywords

atherosclerotic plaque; biomarkers; coronary artery disease; follow up studies; prognosis; radiofrequency intravascular ultrasound

Indexed keywords

DARAPLADIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ACUTE CORONARY SYNDROME; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; EDITORIAL; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INTRAVASCULAR ULTRASOUND; NEAR INFRARED SPECTROSCOPY; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SUDDEN CARDIAC DEATH; VULNERABLE POPULATION; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; INTERVENTIONAL ULTRASONOGRAPHY;

CORONARY ARTERY DISEASE; CORONARY VESSELS; HUMANS; PLAQUE, ATHEROSCLEROTIC; PROGNOSIS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 85054197827     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.09.010     Document Type: Editorial

References (27)

1. Alexander, R.W., Inflammation and coronary artery disease. N Engl J Med 331 (1994), 468–469.
2. Virmani, R., Burke, A.P., Farb, A., Kolodgie, F.D., Pathology of the vulnerable plaque. J Am Coll Cardiol 47 Suppl 8 (2006), C13–C18.
3. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
4. Ridker, P.M., Everett, B.M., Thuren, T., et al., for the CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377 (2017), 1119–1131.
5. Braunwald, E., Epilogue: what do clinicians expect from imagers?. J Am Coll Cardiol 47 Suppl 8 (2006), C101–C103.
6. Motoyama, S., Ito, H., Sarai, M., et al. Plaque characterization by coronary computed tomography angiography and the likelihood of acute coronary events in mid-term follow-up. J Am Coll Cardiol 66 (2015), 337–346.
7. Ferencik, M., Mayrhofer, T., Bittner, D.O., et al. Use of high-risk coronary atherosclerotic plaque detection for risk stratification of patients with stable chest pain. a secondary analysis of the PROMISE randomized clinical trial. JAMA Cardiol 3 (2018), 144–152.
8. Cheng, J.M., Garcia-Garcia, H.M., de Boer, S.P., et al. In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study. Eur Heart J 35 (2014), 639–647.
9. Schuurman, A.S., Vroegindewey, M., Kardys, I., et al. Near-infrared spectroscopy-derived lipid core burden index predicts adverse cardiovascular outcome in patients with coronary artery disease during long-term follow-up. Eur Heart J 39 (2018), 295–302.
10. Stone, G.W., Maehara, A., Lansky, A.J., et al., for the PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 364 (2011), 226–235.
11. Calvert, P.A., Obaid, D.R., O'Sullivan, M., et al. Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study. J Am Coll Cardiol Img 4 (2011), 894–901.
12. Xing, L., Higuma, T., Wang, Z., et al. Clinical significance of lipid-rich plaque detected by optical coherence tomography: a 4-year follow-up study. J Am Coll Cardiol 69 (2017), 2502–2513.
13. Schuurman, A.S., Vroegindewey, M.M., Kardys, I., et al. Prognostic value of intravascular ultrasound in patients with coronary artery disease. J Am Coll Cardiol 72 (2018), 2003–2011.
14. Kubo, T., Maehara, A., Mintz, G.S., et al. The dynamic nature of coronary artery lesion morphology assessed by serial virtual histology intravascular ultrasound tissue characterization. J Am Coll Cardiol 55 (2010), 1590–1597.
15. Zhao, Z., Witzenbichler, B., Mintz, G.S., et al. Dynamic nature of nonculprit coronary artery lesion morphology in STEMI: a serial IVUS analysis from the HORIZONS-AMI trial. J Am Coll Cardiol Img 6 (2013), 86–95.
16. Nicholls, S.J., Puri, R., Anderson, T., et al. Effect of evolocumab on coronary plaque composition. J Am Coll Cardiol 72 (2018), 2012–2021.
17. Nicholls, S.J., Puri, R., Anderson, T., et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316 (2016), 2373–2384.
18. Nicholls, S.J., Tuzcu, E.M., Sipahi, I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007), 499–508.
19. Cholesterol Treatment Trialists’ (CTT) Collaborative, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
20. Sabatine, M.S., Giugliano, R.P., Keech, A.C., et al., for the FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376 (2017), 1713–1722.
21. Serruys, P.W., García-García, H.M., Buszman, P., et al., for the Integrated Biomarker and Imaging Study-2 Investigators. Effects of the direct lipoprotein associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118 (2008), 1172–1182.
22. STABILITY Investigators, Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 370 (2014), 1702–1711.
23. O'Donoghue, M.L., Braunwald, E., White, H.D., et al., for the SOLID-TIMI 52 Investigators. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 312 (2014), 1006–1015.
24. Tian, J., Gu, X., Sun, Y., et al. Effect of statin therapy on the progression of coronary atherosclerosis. BMC Cardiovasc Disord, 12, 2012, 70.
25. Stone, P.H., Maehara, A., Coskun, A.U., et al. Role of low endothelial shear stress and plaque characteristics in the prediction of nonculprit major adverse cardiac events: the PROSPECT Study. J Am Coll Cardiol Img 11 (2018), 462–471.
26. Koskinas, K.C., Ughi, G.J., Windecker, S., Tearney, G.J., Räber, L., Intracoronary imaging of coronary atherosclerosis: validation for diagnosis, prognosis and treatment. Eur Heart J 37 (2016), 524–535a–c.
27. Jaffer, F.A., Verjans, J.W., Molecular imaging of atherosclerosis: clinical state-of-the-art. Heart 100 (2014), 1469–1477.